Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Benzenesulfonic acid, mono- and dialkylation products with C16-20 (even numbered, branched and linear) olefins, calcium salts, calcium carbonate, overbased, including distillates (petroleum), hydrotreated, solvent-refined, solvent-dewaxed, or catalytic dewaxed, light or heavy paraffinic C15-C50
EC number: 701-356-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The toxicity of the substance has been assessed by the repeated exposure over a period of 28-days by the three routes of exposure, oral, dermal and inhalation using read across studies .
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study conducted to OECD guidelines to to GLP, and therefore meets the requirements for Klimisch code 1. Study is classified as Klimisch code 2 only because it is based on read across.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- A fuctional observation battery for neurotoxicity was not performed since this test was not par of the OECD 407 guideline at the time the study was performed
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories
- Age at study initiation: 41 days - Route of administration:
- oral: gavage
- Vehicle:
- peanut oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Mixed weekly weight/volume in peanut oil.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Chemical analysis of dosing solutions was conducted to confirm that they were homogeneous and met the desired concentrations.
- Duration of treatment / exposure:
- 29 day treatment duration with a 14 day recovery period.
- Frequency of treatment:
- 7 days/week
- Remarks:
- Doses / Concentrations:
gavage doses of 0, 100, 500 or 1000 mg/kg/bw
Basis:
actual ingested - No. of animals per sex per dose:
- 6
- Control animals:
- yes
- Details on study design:
- - dose selection rationale: Data from a pilot two week repeated dose oral study.
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- Tests applied included; parametric ANOVA with Dunnetts post-hoc test, non parametric Kruskal-Walls and Mann-Whitney U test, Bartletts test for equal variances, Students t test and Dixons test for rejection of outlying values.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
One animal was sacrificed on Day 0 and one animal was found dead on Day 9, result of probable misdosing. - Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Mean serum cholestrol levels were significantly reduced in the 1000 mg/kg males and females at termination of dosing. This was still significantly reduced in 1000 mg/kg females at the end of the 14 day recovery period.
- Critical effects observed:
- not specified
- Conclusions:
- A NOAEL of 500 mg/kg bw/day was identified in this study.
- Executive summary:
In a subchronic toxicity study calcium sulphonate was administered to 12 Sprague-Dawley rats/sex/dose in the control and top dose groups and 6 animals Sprague-Dawley rats/sex/dose in the low and mod dose via gavage at dose levels of 0, 100, 500 or 1000 mg/kg bw/day). A decrease in serum cholesterol levels occurred in the top dose group. The LOAEL is 1000 mg/kg bw/day, based on a decrease in serum cholesterol at the top dose. The NOAEL is 500 mg/kg bw/day. This subchronic toxicity study in the rat is acceptable and satisfies the guideline requirement for a subchronic oral study (OPPTS 870.3100; OECD 408) in rats.
Reference
Table 1: Average body weights and body weight gains during 29 days of treatment
Dose rate (mg/kg |
Body Weights (g)
|
Total Weight Gain |
|||||
Week 0 |
Week 1 |
Week 2 |
Week 3 |
Week 4 |
g |
% of control |
|
Male |
|||||||
0 |
195 |
243 |
286 |
323 |
352 |
157 |
N/A |
100 |
196 |
245 |
298 |
340 |
374 |
178 |
111 |
500 |
200 |
245 |
289 |
329 |
362 |
162 |
103 |
1000 |
193 |
240 |
283 |
315 |
346 |
153 |
97 |
Female |
|||||||
0 |
155 |
175 |
194 |
213 |
223 |
68 |
N/A |
100 |
156 |
174 |
194 |
215 |
228 |
72 |
106 |
500 |
154 |
175 |
190 |
212 |
221 |
67 |
99 |
1000 |
155 |
174 |
195 |
212 |
224 |
69 |
101 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- There are two Klimisch score 1 read across studies avaiable.
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1986
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study conducted to OECD guidelines and to GLP, and therefore meets the criteria for Klimisch code 1. Study is classified as Klimisch code 2 only because it is based on read across.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River
- Age at study initiation: males, 6 weeks; females, 7 weeks
- Weight at study initiation: males, 205-232g; females 156-186g
- Housing: suspended wire mesh cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-26°C
- Humidity (%): 20-76%
- Photoperiod (hrs dark / hrs light): 12 hours light/dark cycle - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: unchanged (no vehicle)
- Remarks on MMAD:
- MMAD / GSD: MMAD 3.3-3.7 µm
GSD 2.0-2.1 µm - Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus:Glass and stainless steel exposure chambers
- System of generating particulates/aerosols:
- Temperature, humidity, pressure in air chamber: 21-26°C, 20-76%
- Air flow rate: 210-215 pm
- Air change rate: 4.8/minute
- Method of particle size determination: Delron DCI-6 cascade impactor
TEST ATMOSPHERE
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Concentration measured by gravimetric analysis.
- Duration of treatment / exposure:
- 6 hours per day for 28 days.
- Frequency of treatment:
- 5 days per week.
- Remarks:
- Doses / Concentrations:
49.5, 156, 260 mg/m3
Basis:
analytical conc. - No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent no treatment
- Positive control:
- None.
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Prior to terminal sacrifice
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: All animals
- Parameters examined: Haemoglobin concentration, haematocrit, erythrocyte count, platelet count, clotting time, total and differential leukocyte count
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Prior to terminal sacrifice
- Animals fasted: No data
- How many animals: All animals
URINALYSIS: Yes
- Time schedule for collection of urine: Prior to terminal sacrifice
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- gross pathology on all animals
GROSS PATHOLOGY: Yes (see table)
HISTOPATHOLOGY: Yes (see table) - Statistics:
- ANOVA with Dunnets test
Regression analysis
Krusal-Walis and Dunns summed rank test
Jonsheere's test for monotonic trend - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
CLINICAL SIGNS AND MORTALITY
No mortality occurred during the test.
BODY WEIGHT AND WEIGHT GAIN
Bodyweight gain was decreased in treated animals, although this was not statistically significant.
FOOD CONSUMPTION
Not measured
FOOD EFFICIENCY
Not measured
WATER CONSUMPTION
Not measured
OPHTHALMOSCOPIC EXAMINATION
Not measured
HAEMATOLOGY
Statistically significant differences were observed in females. Specifically; increased haematocrit in the low dose group.
CLINICAL CHEMISTRY
Statistically significant differences were observed in females. Specifically; increased creatine phospholinase in the mid and top dose groups and sodium in the top dose group.
NEUROBEHAVIOUR
Not measured
ORGAN WEIGHTS
Statistically significant increased lung weights and lung to body weight ratios were observed in a dose dependant manner in the mid and top dose groups.
GROSS PATHOLOGY
Gross lesions were sporadic and were not considered to be caused by the test article.
HISTOPATHOLOGY: NON-NEOPLASTIC
A higher incidence of accumulations of intraalveolar macrophages and hyperplasia/hypertrophy of bronchiole epithelium was seen in the lungs of the treated animals. These were dose related at the mid and top dose levels.
- Dose descriptor:
- NOAEL
- Effect level:
- 49.5 mg/m³ air (analytical)
- Sex:
- male/female
- Basis for effect level:
- other: Statistically significant dose related increase in lung weight and relative lung weights with corresponding accumulations of intraalveolar macrophages and hyperplasia/hypertrophy of the bronchiole epithelium.
- Critical effects observed:
- not specified
- Conclusions:
- A NOAEL of 49.5 mg/m³ was identified for males and females, based on increased lung weight and microscopic changes of the lung.
- Executive summary:
In a subacute inhalation toxicity study, a petroleum derived calcium salt was administered to 5 Sprague-Dawley rats/sex/concentration by whole body exposure at concentrations of 0, 49.5, 156 or 260 mg/m³ for 6 hours per day, 5 days/week for a total of 28 days.
Statistically significant, dose related increases in lung weights occurred in the mid and top dose groups, with corresponding increases in intraalveolar macrophages and hyperplasia/hypertrophy of bronchiole epithelium. The LOAEL is 156 mg/m³, based on effects in the lung. The NOAEL is 49.5 mg/m³.
Reference
Table 1: Average body weights and body weight gains during 28 days of treatment
Analytical concentration (mg/L) |
Body Weights (g) |
Total Weight Gain |
|||||
Week 0 |
Week 1 |
Week 2 |
Week 3 |
Week 4 |
g |
% of control |
|
Male |
|||||||
0 |
217 |
249 |
295 |
336 |
369 |
152 |
|
LCT |
216 |
248 |
294 |
331 |
359 |
143 |
94 |
MCT |
215 |
247 |
302 |
346 |
384 |
169 |
111 |
HCT |
215 |
243 |
285 |
319 |
347 |
132 |
87 |
Female |
|||||||
0 |
171 |
185 |
206 |
223 |
239 |
68 |
|
LCT |
169 |
185 |
205 |
220 |
232 |
63 |
93 |
MCT |
168 |
181 |
203 |
219 |
229 |
61 |
90 |
HCT |
172 |
186 |
205 |
223 |
238 |
66 |
97 |
Table 2 Selected haematology, clinical chemistry and pathology findings
Doses (unit) |
0 |
50 |
150 |
250 |
0 |
50 |
150 |
250 |
male |
female |
|||||||
Number of animals/group |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
Haematology(day x) |
|
|
|
|
|
|
|
|
- RBC (TERA/L) |
6.62 |
6.89 |
6.66 |
6.52 |
6.60 |
6.90 |
6.59 |
6.70 |
- MCV (FL) |
- |
- |
- |
- |
- |
- |
- |
- |
- HCT (L/L) |
46 |
47 |
46 |
43 |
46 |
48 |
47 |
44 |
- HGB (MMOL/L) |
16.1 |
16.7 |
16.1 |
15.5 |
15.5 |
16.6 |
16.1 |
15.5 |
- WBC (GIGA/L) |
13.9 |
13.7 |
12.9 |
10.5 |
9.0 |
12.8 |
11.5 |
13.8 |
Blood chemistry(day x) |
|
|
|
|
|
|
|
|
- sodium (MMOL/L) |
146 |
146 |
147 |
146 |
145 |
143 |
144 |
141 |
- potassium (MMOL/L) |
4.4 |
4.4 |
4.5 |
4.3 |
4.3 |
4.3 |
4.3 |
4.3 |
- chloride (MMOL/L) |
101 |
102 |
102 |
102 |
102 |
102 |
102 |
101 |
- gobulin (G/L) |
2.2 |
2.3 |
2.4 |
2.0 |
2.1 |
2.1 |
2.1 |
2.0 |
- cholesterol (MMOL/L) |
56 |
53 |
63 |
55 |
59 |
75 |
60 |
69 |
- triglyceride (MMOL/L) |
45 |
39 |
54 |
35 |
30 |
24 |
25 |
25 |
Pathology |
|
|
|
|
|
|
|
|
Accumulation of intraalveolar macrophages |
3 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
Bronchiolar epithelium: hyperplasia/hypertrophy |
3 |
4 |
5 |
5 |
4 |
5 |
5 |
5 |
Table 3: Absolute and relative organ weights
|
Males |
Females |
|||||||
DAILY DOSE |
0 |
50 |
150 |
250 |
0 |
50 |
150 |
250 |
|
NUMBER OF ANIMALS |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
|
BODY WEIGHT (g)a |
335 |
323 |
346 |
313 |
213 |
204 |
204 |
208 |
|
BRAIN |
|
|
|
|
|
|
|
|
|
Absolute Weighta |
g |
1.976 |
1.939 |
2.032 |
1.943 |
1.900 |
1.876 |
1.856 |
1.830 |
Per Body Weighta |
% |
5.93 |
6.03 |
5.90 |
6.21 |
8.96 |
9.20 |
9.12 |
8.84 |
ADRENALS |
|
|
|
|
|
|
|
|
|
Absolute Weighta |
g |
0.051 |
0.052 |
0.054 |
0.054 |
0.068 |
0.069 |
0.070 |
0.060 |
Per Body Weighta |
% |
1.52 |
1.63 |
1.56 |
1.71 |
3.21 |
3.37 |
3.44 |
2.90 |
Per Brain Weighta |
% |
|
|
|
|
|
|
|
|
HEART |
|
|
|
|
|
|
|
|
|
Absolute Weighta |
g |
1.220 |
1.173 |
1.179 |
1.122 |
0.803 |
0.801 |
0.753 |
0.793 |
Per Body Weighta |
% |
3.64 |
3.65 |
3.41 |
3.59 |
3.79 |
3.92 |
3.70 |
3.82 |
Per Brain Weighta |
% |
|
|
|
|
|
|
|
|
KIDNEYS |
|
|
|
|
|
|
|
|
|
Absolute Weighta |
g |
2.592 |
2.779 |
3.054 |
2.704 |
1.745 |
1.696 |
1.694 |
1.883 |
Per Body Weighta |
% |
7.79 |
8.61 |
8.81 |
8.61 |
8.16 |
8.32 |
8.29 |
9.05 |
Per Brain Weighta |
% |
|
|
|
|
|
|
|
|
LIVER |
|
|
|
|
|
|
|
|
|
Absolute Weighta |
g |
10.775 |
10.306 |
11.470 |
9.999 |
7.020 |
6.464 |
6.789 |
7.357 |
Per Body Weighta |
% |
3.22 |
3.20 |
3.31 |
3.18 |
3.30 |
3.17 |
3.33 |
3.53 |
Per Brain Weighta |
% |
|
|
|
|
|
|
|
|
SPLEEN |
|
|
|
|
|
|
|
|
|
Absolute Weighta |
g |
0.670 |
0.569 |
0.652 |
0.594 |
0.426 |
0.441 |
0.471 |
0.484 |
Per Body Weighta |
% |
2.00 |
1.77 |
1.88 |
1.89 |
2.01 |
2.17 |
2.30 |
2.34 |
Per Brain Weighta |
% |
|
|
|
|
|
|
|
|
TESTES |
|
|
|
|
n.a.b |
n.a.b |
n.a.b |
n.a.b |
|
Absolute Weighta |
g |
3.187 |
3.072 |
2.796 |
3.135 |
n.a.b |
n.a.b |
n.a.b |
n.a.b |
Per Body Weighta |
% |
9.54 |
9.54 |
8.16 |
10.02 |
n.a.b |
n.a.b |
n.a.b |
n.a.b |
Per Brain Weighta |
% |
|
|
|
|
n.a.b |
n.a.b |
n.a.b |
n.a.b |
LUNGS |
|
|
|
|
|
|
|
|
|
Absolute Weighta |
g |
1.306 |
1.302 |
1.515 |
1.537 |
1.051 |
1.127 |
1.138 |
1.338 |
Per Body Weighta |
% |
3.91 |
4.05 |
4.39 |
4.91 |
4.93 |
5.52 |
5.59 |
6.46 |
Per Brain Weighta |
% |
|
|
|
|
|
|
|
|
OVARIES |
n.a.b |
n.a.b |
n.a.b |
n.a.b |
0.0921 |
0.0768 |
0.0943 |
0.0742 |
|
Absolute Weighta |
g |
n.a.b |
n.a.b |
n.a.b |
n.a.b |
4.34 |
3.77 |
4.62 |
3.56 |
Per Body Weighta |
% |
n.a.b |
n.a.b |
n.a.b |
n.a.b |
|
|
|
|
Per Brain Weighta |
% |
n.a.b |
n.a.b |
n.a.b |
n.a.b |
|
|
|
|
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 49.5 mg/m³
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The read across study has a Klimisch score of 1.
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study meets the criteria for Klimisch code 1. Study is classified as Klimisch code 2 only because it is based on read across.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- Deviations:
- no
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Sprague Dawley CD rats, 8-9 weeks of age at initiation
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- test substance was applied undiluted to the clipped dorsal surface for periods of 6h per day of study. material was held in place by a gauze patch secured with tape. after each exposure period the treated area was wiped. the procedure was repeated daily for 28d.
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 6h per day for 28d
- Frequency of treatment:
- daily
- Remarks:
- Doses / Concentrations:
0, 100,300 and 1000 mg/kg bwt
Basis:
nominal per unit body weight - No. of animals per sex per dose:
- 5
- Control animals:
- yes, sham-exposed
- Positive control:
- none
- Observations and examinations performed and frequency:
- clinical observations daily
dermal reposes on days 0,1,4,7,11,14,18,21,25 and prior to blood collection on d28
body weight and food consumption during treatment and recovery
Hematology and clinical chemistry at termination of treatment and recovery
Microscopic examination on all animals - Sacrifice and pathology:
- full range of evaluations performed
- Statistics:
- ANOVA with Dunnets test, Kruskal-Walis, Dunns summed rank test , Jonkheere test for monotonic trend, Students t test
- Clinical signs:
- no effects observed
- Dermal irritation:
- effects observed, treatment-related
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- No mortality occurred during the study. Low incidences of very slight erythema, desquamation and / or pinpoint scabbing were observed sporadically in all treated animals. All animals were free of edema during the study. Body weights and food consumption were unremakable. There were no treatment related differences in heamatology. Differences from control were noted for several heamatology parameters including a statistically significant increase in mean % of neutrophils of 300 and 1000 mg/kg females and a decrease in mean % of lymphocytes in the 1000mg/kg females compared to controls on d28. In the absence of differences from control in absolute white blood cell counts, these findings were not considered related to treatment. There was a statistically significant decrease in mean corpuscular haemoglobin concentration in the male satellite animals from d28-42. In the absence of other significant findings these small differences were not considered clinically significant. Serum chemistry values were unremakable. Gross mostmortem findings were considered incidental and unrelated to treatment. There were no alterations in organ weights that were attributed to treatment.There were no test material related microscopic findings noted in any group. Effects on the skin were seen in all groups including control but tended to increase in male treated animals and females in the 300 and 1000 mg.kg groups, indicating a mild irritant effect of the test article.
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: no adverse effects at any concentration tested
- Critical effects observed:
- not specified
- Conclusions:
- No evidence of systemic toxicity via the dermal route.
- Executive summary:
the test article exhibited no evidence of systemic toxicity via the dermal route under the conditions of this study. A NOAEL of >1000 mg/kg bw was established.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The NOEAL was selected from a Klimisch score 1 study. A lower quality study is also available.
Additional information
The repeat dose toxicity has been determined by subacute 28-day toxicity studies by oral, dermal and inhalation exposure. Based on the data available, the substance may have the potential for haemotological effects with a reduction in cholesterol observed in one of the studies by oral exposure. Affects observed in the repeat dose inhalation toxicity study available demonstrated enlarged lungs in high and intermediate dose animals which are likely to be physical effects due to the inhalation of mineral oil and not necessarily a direct toxicological effect of the registered substance.
Furthermore, one dermal repeat dose study exists noting effects which resulted in the Study Director being unable to assign a NOAEL. Due consideration of these data has been taken, but the results are considered not representative of the toxicological effects of the substance since the observations have not been repeated in the remaining study with dermal exposure, nor following exposure by oral and inhalation routes which are generally considered to represent greater systemic exposure routes. Furthermore, effects to the testes of male rats were not been observed in the reproductive toxicity study. In consequence, although data are not available to adequately determine the cause of these effects, the fact that no similar observations have been found in any other study undertaken is considered adequate justification to regard these data as not representative of the toxicological profile of the registered substance.
Notwithstanding these effects, no further effects were observed in the studies and each study achieved a NOAEL. The data are therefore considered adequate to assess the toxicological profile of the substance and for the purposes of classification.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The NOAEL was selected from the most conservative value of the two available read-across studies.
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
There is only one read across study available.
Justification for selection of repeated dose toxicity inhalation - local effects endpoint:
Any local effects will be covered in the NOAEL for systemic effects.
Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
The NOAEL was selected from the higher quality subacute dermal study.
Justification for selection of repeated dose toxicity dermal - local effects endpoint:
All local effects will be covered in the NOAEL for systemic effects.
Repeated dose toxicity: via oral route - systemic effects (target organ) cardiovascular / hematological: other
Repeated dose toxicity: inhalation - systemic effects (target organ) respiratory: lung
Justification for classification or non-classification
In accordance with the criteria for classification as defined in Annex I, Regulation 1272/2008, the test material does not require classification for repeated dose toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.